display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMblaze-370 ...
atezolizumab plus bevacizumab BACCI BACCI
atezolizumab plus cometinib IMblaze-370 ...
avelumab based treatment
avelumab alone SAMCO-PRODIGE 54
Immune checkpoint association
durvalumab plus tremelimumab CO.26 study
nivolumab plus ipilimumab CheckMate 8HW

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons